Spotlight on Pegfilgrastim in Chemotherapy-Induced Neutropenia

被引：0
|
作者：
James E. Frampton
Gillian M. Keating
机构：
[1] Adis International Inc.,
来源：
BioDrugs | 2005年 / 19卷
关键词：
Breast Cancer; Acute Myeloid Leukemia; Febrile Neutropenia; Filgrastim; Chemotherapy Cycle;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Pegfilgrastim (Neulasta®), the sustained-duration form of filgrastim (recombinant human granulocyte colony-stimulating factor [G-CSF]), is created by the addition of a polyethylene glycol (PEG) moiety to filgrastim. Its approved indication in the US is to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.
引用
收藏
页码：405 / 407
页数：2
相关论文
共 50 条
  • [31] Quality of life and chemotherapy-induced neutropenia
    Padilla, G
    Ropka, ME
    CANCER NURSING, 2005, 28 (03) : 167 - 171
  • [32] Prophylaxis hope for chemotherapy-induced neutropenia
    Bosch, X
    LANCET ONCOLOGY, 2005, 6 (11): : 831 - 831
  • [33] Non-interventional Study for the Treatment of Neutropenia Use of Pegfilgrastim for chemotherapy-induced Neutropenia (NADIR) - Study of AUO AP 74/13
    Wuelfing, C.
    Rexer, H.
    UROLOGE, 2016, 55 (01): : 76 - 77
  • [34] Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
    Derek Weycker
    Xiaoyan Li
    Jacqueline Figueredo
    Rich Barron
    Spiros Tzivelekis
    May Hagiwara
    Supportive Care in Cancer, 2016, 24 : 2309 - 2316
  • [35] Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015
    Weycker, Derek
    Bensink, Mark
    Lonshteyn, Alexander
    Doroff, Robin
    Chandler, David
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (12) : 2107 - 2113
  • [36] Comparison of Hospitalization Risk and Associated Costs Among Patients Receiving Sargramostim, Filgrastim, and Pegfilgrastim for Chemotherapy-Induced Neutropenia
    Weycker, Derek
    Barron, Richard L.
    CANCER, 2010, 116 (12) : 3073 - 3073
  • [37] Prophylactic pegfilgrastim is safe and effective for chemotherapy-induced neutropenia in patients with Hodgkin disease and non-Hodgkin lymphoma
    Gregory, S
    Grigg, A
    Moore, T
    PROCEEDINGS OF THE XVII MEETING INTERNATIONAL SOCIETY OF HAEMATOLOGY (EUROPEAN AND AFRICAN DIVISION), 2003, : 231 - 237
  • [38] A Pharmacokinetic and Dose Escalation Study of Pegfilgrastim (KRN125) in Lung Cancer Patients with Chemotherapy-induced Neutropenia
    Yamamoto, Nobuyuki
    Sekine, Ikuo
    Nakagawa, Kazuhiko
    Takada, Minoru
    Fukuoka, Masahiro
    Tanigawara, Yusuke
    Saijo, Nagahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (07) : 425 - 430
  • [39] Comparison of Hospitalization Risk and Associated Costs Among Patients Receiving Sargramostim, Filgrastim, and Pegfilgrastim for Chemotherapy-Induced Neutropenia
    Heaney, Mark L.
    Toy, Edmond L.
    Vekeman, Francis
    Laliberte, Francois
    Dority, Bree L.
    Perlman, Daniel
    Barghout, Victoria
    Duh, Mei Sheng
    CANCER, 2009, 115 (20) : 4839 - 4848
  • [40] Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis: a retrospective evaluation using Medicare claims
    Weycker, Derek
    Hanau, Ahuva
    Lonshteyn, Alexander
    Bowers, Charles
    Garawin, Tamer
    Bensink, Mark
    Chandler, David
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (04) : 725 - 730
12345